Cargando…

PIM-1 kinase: a potential biomarker of triple-negative breast cancer

Triple-negative breast cancer is associated with a poor prognosis, and effective biomarkers for targeted diagnosis and treatment are lacking. The tumorigenicity of the provirus integration site for Moloney murine leukemia virus 1 (PIM-1) gene has been studied for many years. However, its significanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jieying, Tang, Guangyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690594/ https://www.ncbi.nlm.nih.gov/pubmed/31496730 http://dx.doi.org/10.2147/OTT.S212752

Ejemplares similares

ICAM1-Targeting Theranostic Nanoparticles for Magnetic Resonance Imaging and Therapy of Triple-Negative Breast Cancer
por: Chen, Jieying, et al.
Publicado: (2022)

PIM Kinase as an Executional Target in Cancer
por: Zhang, Xinning, et al.
Publicado: (2018)

Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice
por: An, Ningfei, et al.
Publicado: (2013)

Protein kinase PIM2: A simple PIM family kinase with complex functions in cancer metabolism and therapeutics
por: Wang, Yixin, et al.
Publicado: (2021)

PIM Kinases in Multiple Myeloma
por: Wu, Jian, et al.
Publicado: (2021)

Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer
por: Shang, Mao, et al.
Publicado: (2018)

AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer
por: Cao, Wei, et al.
Publicado: (2019)

Inflammation and stem markers association to PIM1/PIM2 kinase-induced tumors in breast and uterus
por: Jiménez-García, Manuel-Pedro, et al.
Publicado: (2017)

Extracellular Vesicles in Triple–Negative Breast Cancer: Immune Regulation, Biomarkers, and Immunotherapeutic Potential
por: Das, Kaushik, et al.
Publicado: (2023)

Targeting the Pim kinases in multiple myeloma
por: Keane, N A, et al.
Publicado: (2015)

Immune-related biomarkers in triple-negative breast cancer
por: Zhang, Juan, et al.
Publicado: (2021)

New Biomarkers and Treatment Advances in Triple-Negative Breast Cancer
por: El Hejjioui, Brahim, et al.
Publicado: (2023)

Triple-negative breast cancer and the potential for targeted therapy
por: Jhan, Jing-Ru, et al.
Publicado: (2017)

The prognostic and predictive potential of Ki-67 in triple-negative breast cancer
por: Zhu, Xiuzhi, et al.
Publicado: (2020)

The role of PIM1/PIM2 kinases in tumors of the male reproductive system
por: Jiménez-García, Manuel Pedro, et al.
Publicado: (2016)

Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers
por: Limsakul, Praopim, et al.
Publicado: (2023)

PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer
por: Spasojevic, Caroline, et al.
Publicado: (2018)

Targeting Pim kinases in hematological cancers: molecular and clinical review
por: Bellon, Marcia, et al.
Publicado: (2023)

The Role of PIM Kinases in Pediatric Solid Tumors
por: Julson, Janet Rae, et al.
Publicado: (2022)

Targeting PIM Kinases to Improve the Efficacy of Immunotherapy
por: Clements, Amber N., et al.
Publicado: (2022)

Pim Kinases: Important Regulators of Cardiovascular Disease
por: Nock, Sophie, et al.
Publicado: (2023)

ELOVL2-AS1 inhibits migration of triple negative breast cancer
por: Zhu, Mingda, et al.
Publicado: (2022)

Current advances in biomarkers for targeted therapy in triple-negative breast cancer
por: Fleisher, Brett, et al.
Publicado: (2016)

Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives
por: Cocco, Stefania, et al.
Publicado: (2020)

Circular RNA: A potential diagnostic, prognostic, and therapeutic biomarker for human triple-negative breast cancer
por: Tian, Tian, et al.
Publicado: (2021)

Triple-negative breast cancer
por: Chacón, Reinaldo D, et al.
Publicado: (2010)

Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)

Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer
por: Li, Chia-Jung, et al.
Publicado: (2021)

The Potential of Hormonal Therapies for Treatment of Triple-Negative Breast Cancer
por: Kirkby, Melanie, et al.
Publicado: (2023)

An overview of pim kinase as a target in multiple myeloma
por: Liu, Zhaoyun, et al.
Publicado: (2023)

miRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer
por: Mathe, Andrea, et al.
Publicado: (2015)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker
por: Qureshi, Sadaf, et al.
Publicado: (2022)

Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges
por: Wang, Xiaoxiao, et al.
Publicado: (2023)

Circulating miRNAs in HER2-Positive and Triple Negative Breast Cancers: Potential Biomarkers and Therapeutic Targets
por: Gupta, Ishita, et al.
Publicado: (2020)

LncRNAs as new biomarkers to differentiate triple negative breast cancer from non-triple negative breast cancer
por: Lv, Mingming, et al.
Publicado: (2016)

Exploring specific prognostic biomarkers in triple-negative breast cancer
por: Bao, Chang, et al.
Publicado: (2019)

Phosphorylation of Notch1 by Pim kinases promotes oncogenic signaling in breast and prostate cancer cells
por: Santio, Niina M., et al.
Publicado: (2016)

Characteristics of triple-negative breast cancer
por: de Ruijter, Tim C., et al.
Publicado: (2010)

Theranostics for Triple-Negative Breast Cancer
por: Choi, Hyeryeon, et al.
Publicado: (2023)

The Potential Role of Nanotechnology in Therapeutic Approaches for Triple Negative Breast Cancer
por: Johnson, Rebecca, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_gs2v5k3f9kkl1ntdcmmu7embdo